"Governor's plane makes emergency landing in Van Nuys"
Keep the surveillance schedule: pre-treatment colonoscopy with polyp removal, a repeat at 1 year, then every 5 years, plus 6-monthly bilirubin, alkaline phosphatase, lipase and amylase [1]
Contraindications and Clinical Red Flags Providers must screen thoroughly before initiating therapy
Tissue effects (angiogenesis, VEGF-receptor signaling, growth factor cross-talk) persist much longer than the plasma window
Research applications: NNMT activity assays, NAD/SAM metabolism studies, adipocyte energy-expenditure models
Bioglutide (NA-931) Phase 2: 13.8% Oral Weight Loss The Phase 2 trial reported oral quadruple agonist NA-931 hit 13.8% weight loss with no muscle loss